Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer
NCT00002473 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2013-06-12
Summary
RATIONALE: Kidney-sparing surgery is a less invasive type of surgery for kidney cancer, and may have fewer side effects and improve recovery. It is unknown whether kidney-sparing surgery is more effective than kidney removal in treating kidney cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of surgery to completely remove the kidney with kidney-sparing surgery in treating patients with resectable kidney cancer.
Conditions
Interventions
- PROCEDURE
-
conventional surgery
Sponsors & Collaborators
-
Eastern Cooperative Oncology Group
collaborator NETWORK -
American College of Surgeons
collaborator OTHER -
SWOG Cancer Research Network
collaborator NETWORK -
NCIC Clinical Trials Group
collaborator NETWORK -
European Organisation for Research and Treatment of Cancer - EORTC
lead NETWORK
Principal Investigators
-
Hein van Poppel, MD, PhD · University Hospital, Gasthuisberg
-
Thomas Keane, MD · Emory University
-
Leonard G. Gomella, MD · Sidney Kimmel Cancer Center at Thomas Jefferson University
-
Eila C. Skinner, MD · University of Southern California
-
Laurence H. Klotz, MD · Toronto Sunnybrook Regional Cancer Centre
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1992-03-31
- Primary Completion
- 2011-02-28
Countries
- Canada
Study Locations
More Related Trials
-
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
NCT01120249 ·Status: COMPLETED ·Phase: PHASE3
-
Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy
NCT05941169 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
NCT00030888 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
NCT03189186 ·Status: WITHDRAWN ·Phase: PHASE1
-
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597 ·Status: RECRUITING ·Phase: PHASE3
-
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613 ·Status: COMPLETED ·Phase: PHASE2
-
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
NCT00106301 ·Status: COMPLETED ·Phase: PHASE2
-
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
NCT02724020 ·Status: COMPLETED ·Phase: PHASE2
-
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
NCT03324373 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
NCT00003683 ·Status: COMPLETED ·Phase: PHASE2
-
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
NCT02535351 ·Status: TERMINATED ·Phase: PHASE3
-
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
NCT00009919 ·Status: TERMINATED ·Phase: PHASE2
-
Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
NCT01024205 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
NCT00492258 ·Status: COMPLETED ·Phase: PHASE3
-
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
NCT02595918 ·Status: TERMINATED ·Phase: PHASE1
-
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
NCT00480389 ·Status: COMPLETED ·Phase: PHASE2
-
Participant Reported Outcomes and Treatment Experiences in Kidney Cancer
NCT04472663 ·Status: COMPLETED
-
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
NCT02724878 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
NCT06376669 ·Status: RECRUITING ·Phase: PHASE2
-
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
NCT00126659 ·Status: TERMINATED ·Phase: PHASE2
-
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
NCT00058318 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
NCT00747305 ·Status: TERMINATED ·Phase: PHASE1
-
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
NCT00672178 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
NCT00282048 ·Status: COMPLETED ·Phase: PHASE2